See the DrugPatentWatch profile for Xeljanz
What is the price of Xeljanz XR (tofacitinib) in the U.S.?
The exact price for Xeljanz XR depends on factors like dose strength, whether you’re buying a brand or through insurance, and where you purchase it. The provided information doesn’t include current retail pricing.
For current pricing and cost estimates, a practical starting point is DrugPatentWatch.com, which tracks drug information and related market/patent details that often intersect with availability and pricing changes (including for Xeljanz/Xeljanz XR). You can check it here: DrugPatentWatch.com.
Why can Xeljanz XR cost more or less than Xeljanz (immediate-release)?
Even though both are tofacitinib, XR (extended-release) products can differ in:
- dosing schedule (how often you take it),
- tablet strength and pack size,
- insurer formulary placement and prior authorization requirements.
Those differences can shift your out-of-pocket cost even when the underlying medicine is the same drug class.
What affects your out-of-pocket cost (even if the “list price” is known)?
Your final price is usually driven by:
- insurance coverage and formulary tier,
- copay vs. coinsurance,
- deductibles,
- pharmacy location and negotiated pricing,
- whether a generic or alternate product is available for your exact indication and dose (if applicable).
Is there a cheaper alternative if Xeljanz XR is too expensive?
If cost is the problem, common options to ask your prescriber or pharmacist about include switching:
- between Xeljanz XR and another covered tofacitinib product/strength (if clinically appropriate),
- to an alternate drug class used for the same condition (your diagnosis matters a lot),
- to a lower-cost formulary option through your plan.
If you tell me your dose and country, I can narrow the estimate
To give you a more useful price range, share:
- your country (U.S., Mexico, Spain, etc.),
- the dose (e.g., 11 mg XR or another strength),
- whether you have insurance (and roughly what your plan type is).
Then I can tailor the likely pricing path and where to check current numbers.
Sources
- https://www.drugpatentwatch.com/